USA's QMS Shift: Pure Global on ISO 13485's Hidden Landmines

About this episode

This episode discusses the complexities of the new Quality Management System Regulation in the U.S. and its implications for ISO 13485 certified manufacturers.

This week, MedTech Global Insights tackles the monumental shift in the U.S. regulatory landscape: the new Quality Management System Regulation (QMSR). While the FDA’s alignment with ISO 13485 promises global harmony, we uncover the hidden complexities and critical differences that many manufacturers are overlooking. We dive into why your ISO 13485 certificate is not a golden ticket and discuss the subtle but crucial distinctions in the FDA’s final rule that could put your US market access at risk. Case in Point: Imagine a European MedTech company, fully certified under ISO 13485, that just received an FDA warning letter. Their quality system was audited by a notified body, but it failed a surprise US inspection because their risk management process didn't align with the FDA's specific expectations for device safety, which are layered on top of the ISO standard. How did they miss this critical gap? Key Takeaways: 1. What are the key clauses from the old quality system regulation that the FDA retained in the new QMSR? 2. How does the FDA's definition of "risk management" differ from a standard ISO 13485 interpretation? 3. Is your management review process ready for the scrutiny of…

People in this episode

Host: Ran Chen

Topics covered

• Quality Management System Regulation
• ISO 13485
• FDA compliance
• risk management
• MedTech industry
• regulatory landscape

Keywords

• QMSR
• FDA
• ISO 13485
• risk management
• quality system
• compliance
• MedTech
• regulatory changes

Mentioned in this episode

Organizations: FDA, ISO 13485, Pure Global, European MedTech

More episodes of MedTech Global Insights

• Pure Global: US AI MedTech Rules & The Global Fallout. · May 7, 2026 · 2 min
• Pure Global: USA's LDT Overhaul - Navigating the FDA's New IVD Era · May 6, 2026 · 2 min
• USA MedTech M&A: Pure Global on The Deal Frenzy of 2026. · May 5, 2026 · 2 min
• Pure Global: US Cyber Rules & The MedTech Rejection Wave · May 4, 2026 · 2 min
• EU's AI-MDR Maze: Pure Global on Dual Regulation Traps · May 3, 2026 · 2 min
• Pure Global: US/EU AI Imaging & The Dual-Approval Gambit · May 2, 2026 · 2 min